Phaseline

Companies › PharmaEngine

PharmaEngine: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PEP07
Selective Chk1 (Checkpoint Kinase 1) inhibitor
CHEK1Phase 1Acute Myeloid Leukemia; Advanced Solid TumorDec 2026
PEP08
MTA-cooperative PRMT5 inhibitor
PRMT5Phase 1Advanced Solid TumorDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05659732PEP07Phase 1Acute Myeloid LeukemiaOncologyDec 2026
NCT05983523PEP07Phase 1Advanced Solid TumorOncologyFeb 2027
NCT06973863PEP08Phase 1Advanced Solid TumorOncologyDec 2027

Targets

CHEK1 (1) PRMT5 (1)

Companies with the same targets

Bristol-Myers Squibb Tango Therapeutics Acrivon Therapeutics Bayer IDEAYA Biosciences Amgen Jubilant Therapeutics India Jiangsu Simcere Pharmaceutical AstraZeneca Servier Bio-Innovation

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.